The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V80808 | Monolaurin-d23 (1-Monolaurin-d23) | Monolaurin-d23 is the deuterated form of Monolaurin. | |
|
V79072 | MPI60 | MPI60 is a potent SARS-CoV-2 MPro inhibitor (antagonist) with high antiviral potency, low cytotoxic effect, and high in vitro metabolic stability. | |
|
V41173 | Mpro inhibitor N3 | 884650-98-0 | Mpro inhibitor N3 is a potent SARS-CoV-2 MPro inhibitor (antagonist) with EC50 of 16.77 µM. |
|
V76747 | Mpro inhibitor N3 hemihydrate | Mpro inhibitor N3 hemihydrate is a potent SARS-CoV-2 Mpro inhibitor (antagonist) with EC50 of 16.77 μM against SARS-CoV-2. | |
|
V80847 | MTase-IN-1 | MTase-IN-1 (compound 26) is a potent and specific inhibitor of coronavirus nsp14 N7-methyltransferase with IC50 of 0.72 nM. | |
|
V29216 | Nafamostat (FUT-175) | 81525-10-2 | Nafamostat (formerly also known as FUT-175) is a novel and synthetic serine protease inhibitor, which is used as an anticoagulant during hemodialysis. |
|
V79898 | Nafamostat formate salt-13C6 (Nafamostat formate salt-13C6) | Nafamostat formate salt-13C6 is 13C (carbon 13) labelled Nafamostat. | |
|
V41135 | Narsoplimab (OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)) | 2108782-45-0 | Narsoplimab (OMS 721) is a high-affinity, fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody (mAb) that binds MASP-2 and blocks lectin pathway activation. |
|
V41115 | Nepuvibart (ZRC3308-B10) | 2640224-48-0 | Nepuvibart (ZRC3308-B10) is a monoclonal antibody (mAb) (IgG1 type) targeting SARS-CoV-2. |
|
V51965 | NHC-diphosphate | 39023-73-9 | NHC-diphosphate is the active intracellular metabolite of NHC and exists in the form of diphosphate. |
|
V2402 | Nirmatrelvir (PF-07321332) | 2628280-40-8 | Nirmatrelvir (PF-07321332), the key component ofPaxlovid [Nirmatrelvir (PF-07321332) and ritonavir] which isnewly approved COVID-19 oral antiviral drug,is an orally bioavailable 3C-like protease (3CLPRO) inhibitor with potent antiviral effects against SARS-CoV-2 virus and COVID-19. |
|
V54405 | NK007 | 2488661-53-4 | NK007 is a novel anti-SARS-CoV-2 active molecule with EC50 of 30 nM. |
|
V80974 | NSC89641 | NSC89641 inhibits MERS-CoV Mpro with IC50 < 3.5 μM. | |
|
V54384 | Ogalvibart (C-135-LS; BMS-986414) | 2599039-60-6 | Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (mAb) (IgG1 type). |
|
V85525 | Olgotrelvir sodium (STI-1558 sodium) | 2763596-72-9 | |
|
V17488 | Paquinimod | 248282-01-1 | Paquinimod (ABR‑215757;ABR215757) is a novel and potent S100A9 inhibitorthat can prevent S100A9 binding to TLR-4 (Toll like receptor-4). |
|
V84617 | PB49673382 | 2763495-65-2 | |
|
V41524 | PF-00835231 (PF-835231) | 870153-29-0 | PF-00835231 (PF-835231) is a potent 3CLpro [main protease (Mpro)] inhibitor developed by Pfizer for COVID-19treatment. |
|
V54391 | Plonmarlimab (TJ003234; TJM2) | 2377482-36-3 | Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody (mAb). |
|
V54411 | PLpro-IN-1 | 1093070-10-0 | PLpro-IN-1 (Compound 2) is a SARS-CoV PLpro inhibitor (IC50= 8.7 μM). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
